TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

The Unexpected Benefits of Clinical Trial Disclosure

newseditor

April 2, 2020


As seen on World Pharma Today – Posted April 2, 2020 – Original Article


April 2, 2020 | By Thomas Wicks | Patients, clinical trial sponsors and institutions are starting to benefit from increased transparency commitments and significant investments in trial data disclosure. 

To make an ever-broader scope of trial data public, leading pharmaceutical organizations have been refining their processes and enhancing the quality of the source data, always keeping the ultimate disclosure in mind. These improvements not only result in a more efficient global disclosure but also directly support patient communication initiatives and trial recruitment.

Continued on World Pharma Today